UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.
Nurix Therapeutics, a US-based oncology therapy developer based on research at University of California (UC), Berkeley and UC San Francisco, has filed to raise up to $100m in an initial public offering that would provide an exit for pharmaceutical producer Celgene.
Founded in 2009 as Kura Therapeutics, Nurix is developing small molecule drugs intended to treat cancer and immune disorders by modulating levels of cellular protein. It was co-founded by John Kuriyan and Michael Rapé from UC Berkeley,…
